"Yearly CT scans of high-risk lung cancer patients has increased the early diagnosis of lung cancer as well as the identification of pulmonary nodules. Yet not all lung nodules are cancerous. The BDX-XL2 test has shown early promise in ruling out cancer through blood samples, including a finding by the pulmonary nodule plasma proteomic classifier (Panoptic) trial indicating that the BDX-XL2 biomarker could lead to a 40% reduction in invasive procedures on benign nodules.”